News for Capricor Therapeutics, Inc. (CAPR)

**media[560229]**

We came across a bullish thesis on Capricor Therapeutics, Inc. (CAPR) on wallstreetbets Subreddit Page by androidmj. In this article, we will summarize the bulls’ thesis on CAPR.

California-based GigaCloud Technology Inc. (GCT) is down over 21 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

**media[556676]**

Capricor Therapeutics filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD cardiomyopathy. Read why CAPR stock is a Buy.

**media[536796]**

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payme

Capricor Therapeutics (CAPR) stock gains as the company completes the U.S. marketing application for lead drug deramiocel in Duchenne muscular dystrophy. Read more here.

**media[504255]**

Capricor Therapeutics, Inc. (CAPR) experienced a significant stock price increase of 5.05%, reaching $13.73 per share with a trading volume of 406,112 shares. T

Capricor Therapeutics, Inc. (CAPR) experienced a significant stock decline of 5.09%, trading at $13.61 with a volume of 456,003 shares. The biotech company repo

Capricor Therapeutics raised $86.3 million in a public offering, ensuring sufficient cash runway to fund operations into 2027. Read my analysis on CAPR stock.

U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Wednesday. Shares of America’s Car-Mart, Inc. CRMT rose sharply during Thur...

Israel-based PainReform Ltd. (PRFX), a clinical stage specialty pharmaceutical company is up over 142 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of Verint Systems Inc. VRNT rose sharply in today's pre-market trading after the company reported a year-over-year increase in third-quarter financial re...

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics ( CAPR), a biotechnology company developing transformative cell and exosome-based therapeut

**media[481372]**

Capricor Therapeutics, Inc. (CAPR) saw a notable stock increase of 5.04%, reaching $19.97 per share. The trading volume was approximately 991,132 shares, with a

Capricor Therapeutics, Inc. (CAPR) experienced a notable stock price increase, rising by 5.40%. The stock is currently priced at $20.09 per share with a trading